ZURA BIO LIMITED Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ZURA BIO LIMITED stock issued during period, value, conversion of convertible securities for the quarter ending 2023-12-31 was $0.00.
- ZURA BIO LIMITED stock issued during period, value, conversion of convertible securities for the quarter ending 2023-09-30 was $0.00.
- ZURA BIO LIMITED stock issued during period, value, conversion of convertible securities for the quarter ending 2023-06-30 was $0.00.
- ZURA BIO LIMITED stock issued during period, value, conversion of convertible securities for the quarter ending 2023-03-31 was $14.69M.
- ZURA BIO LIMITED stock issued during period, value, conversion of convertible securities for fiscal 2023 was $14.69M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $14.69M 10-K · filed 2025-03-25 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | |
| 2023-03-31 | $14.69M 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |